AptarGroup, Inc., an international leader in drug delivery, consumer product dispensing, and active material science solutions, declared its patented Cartridge Pump System (CPS).
It is created for the multidose delivery of preserved and non-preserved drug formulations, was newly examined by the U.S. FDA as the drug delivery device in the permission of Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg, the first and foremost nasal spray approved for the treatment of the signs and symptoms of dry eye disease.
TYRVAYA, a positively demanding cholinergic agonist, is the first nasally-administered pharmaceutical therapy to treat the signs and symptoms of dry eye disease to have been approved by the U.S. FDA.
This approval creates Aptar’s Cartridge Pump System, a vital component of the first and only U.S. FDA-approved pharmaceutical therapy to treat the signs and symptoms of dry eye disease, an ophthalmic condition, via the nasal route re-confirms Aptar’s expertise for creating innovative drug delivery solutions.
Stephan B. Tanda, Aptar’s President, and CEO stated, “This acceptance additionally demonstrates the broad prospect for Aptar’s drug delivery solutions and the ongoing market opportunities for nasal drug delivery. We are delighted that our proven CPS nasal system is currently a multidose delivery choice for patients suffering from dry eye disease.”